A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(14 sites)
China
Affiliated Hospital of Hebei University / School of Clinical Medicine, Baoding, Hebei Harbin Medical University Cancer Hospital, Harbin, Heilongjiang The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan Henan Cancer Hospital, Zhengzhou, Henan The First People'S Hospital of Lianyungãng, Lianyungang, Jiangsu Liaoning Cancer Hospital＆Institute, Shenyang, Liaoning Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong Linyi Cancer Hospital, Linyi, Shandong Weifang People'S Hospital, Weifang, Shandong Shanghai Pulmonary Hospital, Shanghai, Shanghai Municipality Shanxi Cancer hospital, Taiyuan, Shanxi The First Affiliated Hospitalof Xi'an Jiaotong University, Xi’an, Shanxi The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan The First Affiliated Hospitalzhejiang University School of Medicine, Hangzhou, Zhejiang Age range
18 Years – 75 Years
Last updated January 2025